Support Options

Submit a Support Ticket

Home Workshops KIST/PU 6th Annual Symposium: High Impact Research to Society About

KIST/PU 6th Annual Symposium: High Impact Research to Society



Published on


In 2006, the South Korean Ministry of Science and Technology selected the KIST and Purdue team project from 20 international research proposals submitted to examine how to learn more about the molecular makeup of diseases.

The $4.5 million research initiative, which spans nine years, now involves more than a dozen of KIST and Purdue researchers, working to advance the role that nanoparticles can play in the diagnosis and treatment of cancer or chronic diseases like diabetes and multiple sclerosis.

The research also focuses on next-generation tools that would aid the medical community in what's known as theragnosis -- combining simultaneous diagnostics and therapeutics.

Sponsored by

Cite this work

Researchers should cite this work as follows:

  • (2011), "KIST/PU 6th Annual Symposium: High Impact Research to Society,"

    BibTex | EndNote



Burton Morgan 121, Purdue University, West Lafayette, IN


See also

No results found.

In This Workshop

  1. KIST/PU Nanostructured Heparin Derivatives as an Angiogenesis Inhibitor

    07 Dec 2011 | Online Presentations | Contributor(s): Youngro Byun

    Although low molecular weight heparin (LMWH) has been known to regulate angiogenesis, tumor growth and metastasis, the administration of heparin for treating cancer is limited in clinical application due to its unsatisfactory therapeutic effects and a strong anticoagulant activity, which induces...

  2. KIST/PU The Professor’s Challenge: To commercialize or not, that is the question?

    06 Dec 2011 | Online Presentations | Contributor(s): J. Paul Robinson

    Outline:Outline the Professors DilemmaShow what the normal criteria for research project direction isDiscuss the Corporate perspectiveDiscuss an example of failed innovationDemonstrate how time can impact an innovative ideaConclusions

  3. KIST/PU Designing a Research Program Around Unmet Clinical Needs

    06 Dec 2011 | Online Presentations | Contributor(s): Alyssa Panitch

  4. KIST/PU Theragnosis – A New Paradigm of Personalized Medicine

    06 Dec 2011 | Online Presentations | Contributor(s): Ick Chan Kwon

    Companion Diagnosis, based on pharmacogenomics, has been recognized as one of most important key representatives of personalized medicine. However, Companion Diagnosis does not provide any clues in developing new ways of therapeutics but it only provides a best choice of drugs based on given..., a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.